Corrigendum: Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab (Annals of Oncology (2017) 28:6 (1368-1379) DOI: 10.1093/annonc/mdx108);Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Annals of Oncology

Volumn 28, Issue 6, 2017, Pages 1368-1379

  Chaput, N ^a,b   Lepage, P ^c   Coutzac, C ^a,b   Soularue, E ^a,b,d   Le Roux, K ^c   Monot, C ^c   Boselli, L ^a   Routier, E ^e   Cassard, L ^a   Collins, M ^b,d   Vaysse, T ^b,d   Marthey, L ^b,d   Eggermont, A ^e   Asvatourian, V ^b,e   Lanoy, E ^b,e   Mateus, C ^b   Robert, C ^b,e   Carbonnel, F ^b,d  

^a CNRS UMS3655   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UMR1319 MICALIS   (France)

^d BICÊTRE HOSPITAL   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Colitis; Ipilimumab; Melanoma; Microbiota

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA; IPILIMUMAB; RNA 16S; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ARTICLE; BACTEROIDES; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COLITIS; DRUG RESPONSE; FAECALIBACTERIUM PRAUSNITZII; FECES MICROFLORA; FIRMICUTES; GEMMIGER FORMICILIS; GENE SEQUENCE; HUMAN; IMMUNOPHENOTYPING; INTESTINE FLORA; METASTATIC MELANOMA; OVERALL SURVIVAL; PERIPHERAL LYMPHOCYTE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; UPREGULATION; AGED; COMPLICATION; FEMALE; GENETICS; INTESTINE; MALE; MELANOMA; METASTASIS; MICROBIOLOGY; MICROFLORA; PATHOLOGY;

AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; COLITIS; FEMALE; HUMANS; INTESTINES; IPILIMUMAB; MALE; MELANOMA; MICROBIOTA; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; RNA, RIBOSOMAL, 16S;

EID: 85021170776     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdz224     Document Type: Erratum

References (44)

1. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26): 2517-2526.
2. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711-723.
3. Schadendorf D, Hodi FS, Robert C et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33(17): 1889-1894.
4. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4): 252-264.
5. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33(17): 1974-1982.
6. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30(21): 2691-2697.
7. Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24(15): 2283-2289.
8. Gupta A, De Felice KM, Loftus EV, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015; 42(4): 406-417.
9. Marthey L, Mateus C, Mussini C et al. Cancer immunotherapy with anti- CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 2016; 10(4): 395-401.
10. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361(21): 2066-2078.
11. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140(6): 1720-1728.e3.
12. Lepage P, Häsler R, Spehlmann ME et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 2011; 141(1): 227-236.
13. Vétizou M, Pitt JM, Daillère R et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350(6264): 1079-1084.
14. Sivan A, Corrales L, Hubert N et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350(6264): 1084-1089.
15. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15(23): 7412-7420.
16. Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371(23): 2189-2199.
17. Seksik P. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52(2): 237-242.
18. Chen H, Liakou CI, Kamat A et al. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA 2009; 106(8): 2729-2734.
19. Read S, Greenwald R, Izcue A et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006; 177(7): 4376-4383.
20. Lukiw WJ. Bacteroides fragilis lipopolysaccharide and inflammatory signaling in Alzheimer's disease. Front Microbiol 2016; 7: 1544.
21. Guigoz Y, Doré J, Schiffrin EJ. The inflammatory status of old age can be nurtured from the intestinal environment. Curr Opin Clin Nutr Metab Care 2008; 11(1): 13-20.
22. Le Chatelier E, Nielsen T, Qin J et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013; 500(7464): 541-546.
23. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105(43): 16731-16736.
24. Devillard E, McIntosh FM, Duncan SH, Wallace RJ. Metabolism of linoleic acid by human gut bacteria: different routes for biosynthesis of conjugated linoleic acid. J Bacteriol 2007; 189(6): 2566-2570.
25. Mathewson ND, Jenq R, Mathew AV et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graftversus- host disease. Nat Immunol 2016; 17(5): 505-513.
26. Smith PM, Howitt MR, Panikov N et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341(6145): 569-573.
27. Gray RJ. A class of $K$-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 1988; 16(3): 1141-1154.
28. Lin G, So Y, Johnston G, Analysing survival data with competing risks using SAS* software. Proc. SAS Glob. Forum 2012 Conference, Cary, NC. SAS Inst. Inc. 2012.
29. Riley JL, Blair PJ, Musser JT et al. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. J Immunol 2001; 166(8): 4943-4948.
30. Lotze MT, Custer MC, Sharrow SO et al. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res 1987; 47(8): 2188-2195.
31. Dubin K, Callahan MK, Ren B et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 2016; 7: 10391.
32. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012; 489(7415): 231-241.
33. Cebula A, Seweryn M, Rempala GA et al. Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. Nature 2013; 497(7448): 258-262.
34. Png CW, Lindén SK, Gilshenan KS et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 2010; 105(11): 2420-2428.
35. Hedin CR, McCarthy NE, Louis P et al. Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings. Gut 2014; 63(10): 1578-1586.
36. Romano E, Kusio-Kobialka M, Foukas PG et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA 2015; 112(19): 6140-6145.
37. Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 2011; 71(16): 5445-5454.
38. Liakou CI, Kamat A, Tang DN et al. CTLA-4 blockade increases IFN - producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 2008; 105(39): 14987-14992.
39. Sim GC, Martin-Orozco N, Jin L et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2014; 124(1): 99-110.
40. Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol 2015; 15(5): 283-294.
41. Chaput N, Flament C, Locher C et al. Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome. Oncoimmunology 2013; 2(2): e23080.
42. Yu A, Snowhite I, Vendrame F et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes 2015; 64(6): 2172-2183.
43. Hodi FS, Chesney J, Pavlick AC et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016; 17(11): 1558-1568.
44. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(13): 1270-1271.